Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell function. RESULTS: Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as compared with glyburide (P<0.001 for both comparisons). The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0.05), and the risk associated with metformin was similar to that with rosiglitazone. Rosiglitazone was associated with more weight gain and edema than either metformin or glyburide but with fewer gastrointestinal events than metformin and with less hypoglycemia than glyburide (P<0.001 for all comparisons). CONCLUSIONS: The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00279045 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TZDs have a high durability of glycemic response, most likely through a potent effect on preserving b -cell function (196).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study examined the impact of lifestyle and medications in a young cohort with diabetes duration of less than a year and found glycaemia to be best managed by the combination of rosiglitazone and metformin, with the addition of lifestyle to metformin being no better than metformin alone161.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [161]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationUse and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Self-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Research works printed but not linked: 3
- 10.1210/jc.82.7.2108 · doi:10.1210/jc.82.7.2108 · Paper page
- Harris SB, 2004, Can Fam Physician, 50, 425
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
Cited by
Items 601–700 of 1,014
Living Dangerously: Protective and Harmful ER Stress Responses in Pancreatic β-Cells
Sharma, R. B., Landa-Galván, H. V., & Alonso, L. C. (2021) · Diabetes · doi:10.2337/dbi20-0033 · Cited by 80
BACH2 inhibition reverses β cell failure in type 2 diabetes models
Son, J., Ding, H., Farb, T. B., Efanov, A. M., Sun, J., Gore, J. L., Syed, S. K., Lei, Z., Wang, Q., Accili, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci153876 · Cited by 73
Disposition of metformin: Variability due to polymorphisms of organic cation transporters
Zolk, O. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.549144 · Cited by 75
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes
Wilding, J. P. H. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01601.x · Cited by 74
Functional herbal food ingredients used in type 2 diabetes mellitus
Li, Y., & Perera, P. (2012) · Pharmacognosy Reviews · doi:10.4103/0973-7847.95863 · Cited by 71
Oguma, T., Nakayama, K., Kuriyama, C., Matsushita, Y., Yoshida, K., Hikida, K., Obokata, N., Tsuda-Tsukimoto, M., Saito, A., Arakawa, K., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.225508 · Cited by 78
Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?
Florez, J. C. (2017) · Diabetologia · doi:10.1007/s00125-017-4227-1 · Cited by 78
The β Cell in Diabetes: Integrating Biomarkers With Functional Measures
Kahn, S. E., Chen, Y., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab021 · Cited by 80
Self-citationLi, N., Yin, L., Shang, J., Liang, M., Liu, Z., Yang, H., Qiang, G., Du, G., & Yang, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115113 · Cited by 78
Review: Metformin: Potential benefits and use in chronic kidney disease
PILMORE, H. L. (2010) · Nephrology · doi:10.1111/j.1440-1797.2010.01328.x · Cited by 69
Rosiglitazone Is Associated with Mortality in Chronic Hemodialysis Patients
Ramirez, S. P. B., Albert, J. M., Blayney, M. J., Tentori, F., Goodkin, D. A., Wolfe, R. A., Young, E. W., Bailie, G. R., Pisoni, R. L., & Port, F. K. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008060579 · Cited by 71
Type 2 diabetes mellitus—current therapies and the emergence of surgical options
Lebovitz, H. E. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.10 · Cited by 76
Oberbach, A., Lehmann, S., Kirsch, K., Krist, J., Sonnabend, M., Linke, A., Tönjes, A., Stumvoll, M., Blüher, M., & Kovacs, P. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0220 · Cited by 70
The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes
Amod, A. (2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872276 · Cited by 76
Aroda, V. R., González-Galvez, G., Grøn, R., Halladin, N., Haluzík, M., Jermendy, G., Kok, A., Őrsy, P., Sabbah, M., Sesti, G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30184-6 · Cited by 68
Pancreatic β-cell heterogeneity in health and diabetes: classes, sources, and subtypes
Miranda, M. A., Macias-Velasco, J. F., & Lawson, H. A. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00649.2020 · Cited by 78
Wolever, T. M. S., Mehling, C. C., Chiasson, J. L., Josse, R. G., Leiter, L. A., Maheux, P., RABASA-LHORET, R. P. R., Rodger, N. W., & Ryan, E. A. (2008) · Diabetologia · doi:10.1007/s00125-008-1093-x · Cited by 74
Liraglutide Effect and Action in Diabetes (LEAD™) trial
Madsbad, S. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.4.2.119 · Cited by 77
Esposito, K., Chiodini, P., Maiorino, M. I., Bellastella, G., Capuano, A., & Giugliano, D. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005442 · Cited by 68
Predictors and Impact of Intensification of Antihyperglycemic Therapy in Type 2 Diabetes
McEwen, L. N., Bilik, D., Johnson, S. L., Halter, J. B., Karter, A. J., Mangione, C. M., Subramanian, U., Waitzfelder, B., Crosson, J. C., & Herman, W. H. (2009) · Diabetes Care · doi:10.2337/dc08-1911 · Cited by 68
Self-citationVerhaegen, A. A., & Gaal, L. F. V. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0719-6 · Cited by 87
Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes
Stage, T. B., Christensen, M. M. H., Jørgensen, N. R., Beck‐Nielsen, H., Brøsen, K., Gram, J., & Frost, M. (2018) · Bone · doi:10.1016/j.bone.2018.04.004 · Cited by 69
The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists
Friedland, S. N., Leong, A., Filion, K. B., Genest, J. J., Lega, I. C., Mottillo, S., Poirier, P., Reoch, J., & Eisenberg, M. J. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.025 · Cited by 74
Care of elderly patients with diabetes mellitus: A focus on frailty
Chen, L., Chen, Y., Lin, M.-H., Peng, L., & Hwang, S. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.08.008 · Cited by 79
Cardiovascular safety of anti-diabetic drugs
Kumar, R. B., Kerins, D. M., & Walther, T. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv035 · Cited by 72
Ji, L., Song, W., Fang, H., Li, W. S., Geng, J., Wang, Y., Guo, L., Cai, H., Yang, T., Li, H., et al. (2021) · 中国科学通报:英文版 · doi:10.1016/j.scib.2021.03.019 · Cited by 74
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
Giglio, R. V., Παπάνας, Ν., Rizvi, A. A., Ciaccio, M., Patti, A. M., Ilias, Ι., Stoian, A. P., Sahebkar, A., Janež, A., & Rizzo, M. (2022) · Medicina · doi:10.3390/medicina58101475 · Cited by 81
Monami, M., Cremasco, F., Lamanna, C., Marchionni, N., & Mannucci, E. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1184 · Cited by 69
Gupta, D., Jetton, T. L., Mortensen, R. M., Duan, S. Z., Peshavaria, M., & Leahy, J. L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801813200 · Cited by 67
Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
Irons, B. K., & Minze, M. G. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s38753 · Cited by 76
PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty
Huang, J. V., Greyson, C. R., & Schwartz, G. G. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024505 · Cited by 78
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
Leahy, J. L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70035-0 · Cited by 67
Dawed, A. Y., Donnelly, L. A., Tavendale, R., Carr, F., Leese, G., Palmer, C. N. A., Pearson, E. R., & Zhou, K. (2016) · Diabetes Care · doi:10.2337/dc15-2464 · Cited by 76
Dailey, G. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.025 · Cited by 66
Russell, S. (2012) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-012-9729-9 · Cited by 77
Ke, C., Stukel, T. A., Shah, B. R., Lau, E., Ma, R. C., So, W.-Y., Kong, A. P., Chow, E., Chan, J. C. N., & Luk, A. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003316 · Cited by 57
Davies, M. J., Kela, R., & Khunti, K. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01330.x · Cited by 66
Hollander, P. L., Li, J., Frederich, R. C., Allen, E., Chen, R. K., & CV181013 Investigators (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111404575 · Cited by 67
Syversen, U., Stunes, A. K., Gustafsson, B. I., Obrant, K. J., Nordsletten, L., Berge, R. K., Thommesen, L., & Reseland, J. E. (2009) · BMC Endocrine Disorders · doi:10.1186/1472-6823-9-10 · Cited by 79
Overview of metformin: special focus on metformin extended release
Ali, S., & Fonseca, V. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.705829 · Cited by 66
Arnold, S. V., Inzucchi, S. E., Echouffo-Tcheugui, J. B., Tang, F., Lam, C. S. P., Sperling, L. S., & Kosiborod, M. (2019) · Circulation Heart Failure · doi:10.1161/circheartfailure.118.005855 · Cited by 70
Controversies in the Diagnosis and Management of NAFLD and NASH.
Rinella, M. E., Loomba, R. S., Caldwell, S. H., Kowdley, K. V., Charlton, M., Tetri, B. A., & Harrison, S. A. (2014) · PubMed Central · Cited by 76
Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?
Malaguarnera, R., Vella, V., Nicolosi, M. L., & Belfiore, A. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00314 · Cited by 69
2023 Guidelines on the management of patients with diabetes - a position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2023) · Current Topics in Diabetes · doi:10.5114/ctd/160061 · Cited by 85
Liu, B., Asare‐Anane, H., Al‐Romaiyan, A., Huang, G.-C., Amiel, S. A., Jones, P. M., & Persaud, S. J. (2009) · Cellular Physiology and Biochemistry · doi:10.1159/000204101 · Cited by 65
Yang, Z., Zhou, Z., Li, X., Huang, G., & Lin, J. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.044 · Cited by 65
Bach, R. G., Brooks, M. M., Lombardero, M., Genuth, S., Donner, T. W., Garber, A., Kennedy, L., Monrad, E. S., Pop-Busui, R., Kelsey, S. F., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000678 · Cited by 65
Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?
Zinman, B. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.003 · Cited by 70
Self-citationThe Effects of Metformin on Ovarian Cancer
Dilokthornsakul, P., Chaiyakunapruk, N., Termrungruanglert, W., Pratoomsoot, C., Saokaew, S., & Sruamsiri, R. (2013) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182a80a21 · Cited by 67
Dağdelen, S., Şener, D., & Bayraktar, M. (2007) · Advances in Therapy · doi:10.1007/bf02877778 · Cited by 65
Pharmacogenomics of Oral Antidiabetic Medications: Current Data and Pharmacoepigenomic Perspective
Manolopoulos, V. G., Ragia, G., & Tavridou, A. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.65 · Cited by 74
Ku, E. J., Lee, D., Jeon, H. J., & Oh, T. K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.04.008 · Cited by 72
Pleiotropic effects of thiazolidinediones
Rizos, C., Liberopoulos, E., Mikhailidis, D., & Elisaf, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.7.1087 · Cited by 65
PPARγ inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats
Lin, T., Yang, R., Tang, C., Lin, C., & Fu, W. (2007) · Bone · doi:10.1016/j.bone.2007.06.017 · Cited by 72
Mamza, J., Marlin, C., Wang, C., Chokkalingam, K., & IDRIS, I. R. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.029 · Cited by 67
The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality
Stafylas, P. C., Sarafidis, P. A., & Lasaridis, A. N. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.06.005 · Cited by 66
Tschöpe, D., Bramlage, P., Binz, C., Krekler, M., Deeg, E., & Gitt, A. K. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-23 · Cited by 67
Adipokines in the treatment of diabetes mellitus and obesity
Catalán, V., Gómez‐Ambrosi, J., Rodríguez, A., Salvador, J., & Frühbeck, G. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802618811 · Cited by 72
Genetics of Gestational Diabetes Mellitus and Type 2 Diabetes
Watanabe, R. M., Black, M. H., Xiang, A. H., Allayee, H., Lawrence, J. M., & Buchanan, T. A. (2007) · Diabetes Care · doi:10.2337/dc07-s205 · Cited by 67
Fate of the beta-cell in the pathophysiology of type 2 diabetes
Campbell, R. K. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09076 · Cited by 69
Ivanova, E. A., Parolari, A., Myasoedova, V. A., Melnichenko, A. А., Bobryshev, Y. V., & Orekhov, A. N. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.05.004 · Cited by 73
MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome
Glintborg, D., & Andersen, M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0373 · Cited by 63
Abdul-Ghani, M., & DeFronzo, R. A. (2017) · Diabetes Care · doi:10.2337/dc16-2368 · Cited by 62
PPARγ agonists delay age‐associated metabolic disease and extend longevity
Xu, L., Ma, X., Verma, N., Pèrié, L., Pendse, J., Shamloo, S., Josephson, A. M., Wang, D., Qiu, J., Guo, M., et al. (2020) · Aging Cell · doi:10.1111/acel.13267 · Cited by 73
Vildagliptin: a new oral treatment for type 2 diabetes mellitus
Mathieu, C. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3005 · Cited by 62
Effects of Thiazolidinediones on Bone Loss and Fracture
Murphy, C. E., & Rodgers, P. T. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k286 · Cited by 65
Jalali, M., Rahimlou, M., Mahmoodi, M., Moosavian, S. P., Symonds, M. E., Jalali, R., Zare, M., Imanieh, M. H., & Stasi, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104799 · Cited by 68
Sheu, W. H., Gantz, I., Chen, M., Suryawanshi, S., Mirza, A., Goldstein, B. J., Kaufman, K. D., & Engel, S. S. (2015) · Diabetes Care · doi:10.2337/dc15-0109 · Cited by 65
Charbonnel, B. H., Steinberg, H. O., Eymard, E., Xu, L., Thakkar, P., Prabhu, V. S., Davies, M. J., & Engel, S. S. (2013) · Diabetologia · doi:10.1007/s00125-013-2905-1 · Cited by 66
Chiu, C., Du, Y., Ou, H., & Beverly, E. A. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s53482 · Cited by 78
Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions
Holstein, A., & Beil, W. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902806424 · Cited by 61
Strategies for preventing type 2 diabetes: an update for clinicians
Khavandi, K., Amer, H., Ibrahim, B., & Brownrigg, J. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313494986 · Cited by 62
Management of Glycemia in Patients With Diabetes Mellitus and CKD
Lubowsky, N. D., Siegel, R. D., & Pittas, A. G. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.08.012 · Cited by 68
Exenatide therapy in insulin-treated type 2 diabetes and obesity
Nayak, U. A., Govindan, J., Baskar, V., Kalupahana, D., & Singh, B. M. (2010) · QJM · doi:10.1093/qjmed/hcq112 · Cited by 62
Kim, J., Jung, M., Lee, J., Son, H., Cha, B., & Chang, S. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04222.x · Cited by 62
Belongie, K., Ferrannini, E., Johnson, K., Andrade‐Gordon, P., Hansen, M. K., & Petrie, J. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182932 · Cited by 64
Metformin monotherapy for adults with type 2 diabetes mellitus
Gnesin, F., Thuesen, A. C. B., Kähler, L. K. A., Madsbad, S., & Hemmingsen, B. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012906.pub2 · Cited by 62
Drugs acting on SUR1 to treat CNS ischemia and trauma
Simard, J. M., WOO, S., Bhatta, S., & Gerzanich, V. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.10.004 · Cited by 63
Cohen, A., & Horton, E. S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182068 · Cited by 62
Chacra, A. R., Tan, G. H., Ravichandran, S., List, J. F., Chen, R. K., & CV181040 Investigators (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111404574 · Cited by 65
The TIDE Trial Investigators (2011) · Diabetologia · doi:10.1007/s00125-011-2357-4 · Cited by 64
Holmberg, A. H., Nilsson, P. M., Nilsson, J.-Å., & Åkesson, K. S. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0843 · Cited by 63
Unraveling the Science of Incretin Biology
Nauck, M. A. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.012 · Cited by 74
Risk of Fractures with Glitazones: A Critical Review of the Evidence to Date
Bodmer, M., Meier, C., KRAENZLIN, M. E., & Meier, C. R. (2009) · Drug Safety · doi:10.2165/00002018-200932070-00001 · Cited by 65
Cefalu, W. T., Buse, J. B., Del Prato, S., Home, P. D., LeRoith, D., Nauck, M. A., Raz, I., Rosenstock, J., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-1395 · Cited by 61
Genuth, S. (2015) · Diabetes Care · doi:10.2337/dc14-0565 · Cited by 60
van Raalte, D. H., & Verchere, C. B. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12935 · Cited by 69
Rates of glycaemic deterioration in a real-world population with type 2 diabetes
Donnelly, L. A., Zhou, K., Doney, A. S. F., Jennison, C., Franks, P. W., & Pearson, E. R. (2018) · Diabetologia · doi:10.1007/s00125-017-4519-5 · Cited by 61
Dahabreh, I. J. (2008) · Clinical Trials · doi:10.1177/1740774508090212 · Cited by 61
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
Smith, R. J., Goldfine, A. B., & Hiatt, W. R. (2016) · Diabetes Care · doi:10.2337/dc15-2237 · Cited by 60
BUNCK, M. C., POELMA, M., EEKHOFF, E. M., SCHWEIZER, A., HEINE, R. J., NIJPELS, G., FOLEY, J. E., & DIAMANT, M. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00168.x · Cited by 61
Exercise Regulation of Marrow Fat in the Setting of PPARγ Agonist Treatment in Female C57BL/6 Mice
Styner, M., Pagnotti, G. M., Galior, K., Wu, X., Thompson, W. R., Uzer, G., Sen, B., Xie, Z., Horowitz, M. C., Styner, M. A., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1213 · Cited by 63
Kashiwagi, A., Akiyama, N., Shiga, T., Kazuta, K., Utsuno, A., Yoshida, S., & Ueyama, E. (2014) · Diabetology International · doi:10.1007/s13340-014-0184-9 · Cited by 60
Interventions to Preserve Beta-Cell Function in the Management and Prevention of Type 2 Diabetes
Page, K. A., & Reisman, T. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0363-2 · Cited by 65
Hypoglycemia and risk of vascular events and mortality: a systematic review and meta-analysis
Yeh, J. S., Sung, S., Huang, H.-M., Yang, H.-L., You, L., Chuang, S., Huang, P.-C., Hsu, P., Cheng, H., & Chen, C. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0803-3 · Cited by 66
Risk of fractures and diabetes medications: a nationwide cohort study
Choi, H. J., Park, C., Lee, Y., Ha, Y., Jang, S., & Shin, C. S. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3595-6 · Cited by 63
PPARγ deacetylation dissociates thiazolidinedione’s metabolic benefits from its adverse effects
Kraakman, M. J., Liu, Q., Postigo-Fernandez, J., Ji, R., Kon, N., Larrea, D., Namwanje, M., Fan, L., Chan, M., Área-Gómez, E., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98709 · Cited by 60
Montoya, P. A., Múñoz, Ó., Cardozo, D. M. G., García, O. M., Fernandez-Ávila, D. G., Casas, L. Á., Bohórquez, L. F., Toro, C. M. A., Carvajal, L., de Peña, D. R., et al. (2016) · Colombia medica · doi:10.25100/cm.v47i2.2207 · Cited by 96
Elbere, I., Silamiķelis, I., Dindune, I. I., Kalniņa, I., Briviba, M., Zaharenko, L., Silamiķele, L., Rovīte, V., Gudrā, D., Konrāde, I., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241338 · Cited by 69
Genetic and biochemical pathways of β‐cell failure in type 2 diabetes
Talchai, C., Lin, H. V., Kitamura, T., & Accili, D. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01115.x · Cited by 63
Metadata
- Authors
- Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., & Viberti, G.
- Affiliations
- University of Washington (US)
- The University of Texas at San Antonio Health Science Center (US)
- GlaxoSmithKline (United States) (US)
- University of Michigan (US)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- George Washington University (US)
- Mount Sinai Hospital (CA)
- University of London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-12-07
- Volume
- 355
- Issue
- 23
- Pages
- 2427-2443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081276121
- Cited by
- 2,962
- References
- 37
- Citations by year
- 2026: 48 · 2025: 64 · 2024: 77 · 2023: 66 · 2022: 88 · 2021: 98 · 2020: 120 · 2019: 102 · 2018: 120 · 2017: 139 · 2016: 163 · 2015: 158 · 2014: 181 · 2013: 202 · 2012: 180
- FWCI
- 163.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, rosiglitazone, metformin, glibenclamide, thiazolidinediones, glycemic control, fasting blood glucose, HbA1c, insulin sensitivity, beta-cell function, cardiovascular events, congestive heart failure, hypoglycemia, weight gain, edema, gastrointestinal adverse effects, drug selection
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glyburide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Cholesterol, LDL, Male, Metformin, Middle Aged, Weight Gain, Proportional Hazards Models, Treatment Outcome, Thiazolidinediones, Waist-Hip Ratio, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.